Literature DB >> 10650029

Chronic fatigue syndrome.

S Reid1, T Chalder, A Cleare, M Hotopf, S Wessely.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10650029      PMCID： PMC1117488          DOI： 10.1136/bmj.320.7230.292

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  36 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  INFECTIOUS MONONUCLEOSIS. 2. RELATION OF BED REST AND ACTIVITY TO PROGNOSIS.

Authors:  W DALRYMPLE
Journal:  Postgrad Med       Date:  1964-04       Impact factor: 3.840

3.  A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome.

Authors:  P K Peterson; A Pheley; J Schroeppel; C Schenck; P Marshall; A Kind; J M Haugland; L J Lambrecht; S Swan; S Goldsmith
Journal:  Arch Intern Med       Date:  1998-04-27

4.  The Sickness Impact Profile: development and final revision of a health status measure.

Authors:  M Bergner; R A Bobbitt; W B Carter; B S Gilson
Journal:  Med Care       Date:  1981-08       Impact factor: 2.983

5.  The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA.

Authors:  G Warren; M McKendrick; M Peet
Journal:  Acta Neurol Scand       Date:  1999-02       Impact factor: 3.209

6.  Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.

Authors:  L M Forsyth; H G Preuss; A L MacDowell; L Chiazze; G D Birkmayer; J A Bellanti
Journal:  Ann Allergy Asthma Immunol       Date:  1999-02       Impact factor: 6.347

7.  Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial.

Authors:  A J Cleare; E Heap; G S Malhi; S Wessely; V O'Keane; J Miell
Journal:  Lancet       Date:  1999-02-06       Impact factor: 79.321

8.  Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome.

Authors:  A J Wearden; R K Morriss; R Mullis; P L Strickland; D J Pearson; L Appleby; I T Campbell; J A Morris
Journal:  Br J Psychiatry       Date:  1998-06       Impact factor: 9.319

9.  The epidemiology of chronic fatigue in San Francisco.

Authors:  L Steele; J G Dobbins; K Fukuda; M Reyes; B Randall; M Koppelman; W C Reeves
Journal:  Am J Med       Date:  1998-09-28       Impact factor: 4.965

10.  Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial.

Authors:  R McKenzie; A O'Fallon; J Dale; M Demitrack; G Sharma; M Deloria; D Garcia-Borreguero; W Blackwelder; S E Straus
Journal:  JAMA       Date:  1998 Sep 23-30       Impact factor: 56.272
View more
  22 in total

Review 1.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

2.  High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome.

Authors:  Thozhukat Sathyapalan; Stephen Beckett; Alan S Rigby; Duane D Mellor; Stephen L Atkin
Journal:  Nutr J       Date:  2010-11-22       Impact factor: 3.271

3.  Fatigue: a practical approach to diagnosis in primary care.

Authors:  Jacques Cornuz; Idris Guessous; Bernard Favrat
Journal:  CMAJ       Date:  2006-03-14       Impact factor: 8.262

Review 4.  Cost-effectiveness acceptability curves and a reluctance to lose.

Authors:  Johan L Severens; Daniëlle E M Brunenberg; Elisabeth A L Fenwick; Bernie O'Brien; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome.

Authors:  P Powell; R P Bentall; F J Nye; R H Edwards
Journal:  BMJ       Date:  2001-02-17

6.  Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Authors:  Ila R Singh; John E Gorzynski; Daria Drobysheva; Leda Bassit; Raymond F Schinazi
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

7.  The efficacy and safety of moxibustion for chronic fatigue syndrome: A protocol for systematic review and meta-analysis.

Authors:  Kaiyang Xue; Yanping Wang; Xianzhu Wang; Pingnan Chen; Caihong Xiao; Jing Fu; Jin Cui
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

8.  A preliminary prospective study of nutritional, psychological and combined therapies for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in a private care setting.

Authors:  Megan Anne Arroll; Alex Howard
Journal:  BMJ Open       Date:  2012-11-19       Impact factor: 2.692

9.  Fatigue Intervention by Nurses Evaluation--the FINE Trial. A randomised controlled trial of nurse led self-help treatment for patients in primary care with chronic fatigue syndrome: study protocol. [ISRCTN74156610].

Authors:  A J Wearden; L Riste; C Dowrick; C Chew-Graham; R P Bentall; R K Morriss; S Peters; G Dunn; G Richardson; K Lovell; P Powell
Journal:  BMC Med       Date:  2006-04-07       Impact factor: 8.775

Review 10.  Caring for medically unexplained physical symptoms after toxic environmental exposures: effects of contested causation.

Authors:  Charles C Engel; Joyce A Adkins; David N Cowan
Journal:  Environ Health Perspect       Date:  2002-08       Impact factor: 9.031
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.